Replies to post #5147 on Biostax Corp (BTAX)

[H1C]

Herold, Dr. Jill Smith conducted Phase 2 trials for LDN for Crohn's. She talks about them in the video I linked to earlier:

The whole thing's worth a watch, because she explains LDN's mechanisms of action so clearly, and gives a nice overview of the trials she's done.

I believe that the FDA relied on Dr. Smith's earlier work in giving IMUN the go-ahead in January 2018 to apply for Phase 3 trials.

Dr. Smith is one of the major patent owners that IMUN bought IP from. She likely was paid partly in equity in IMUN.

I too am curious how they'll fund the Phase 3 trials. I hope you and dwarren are right, and that it'll be from a combination of revenue from Africa, and a US government grant. LDN is exactly the kind of drug that CMS desperately needs to curb Medicare and Medicaid costs.

The 10-K is due before the end of the quarter, so hopefully we will get more details this week.

[noreen]

Was LDN in stage 3 trials before this announcement so this a continuation of the trial from a few years ago, or a completely new trial all together?

Someone correct me if I'm wrong, but I believe the following is the last publication regarding the alleged 2013 Phase 3 FDA meeting for Crohn's.

https://backend.otcmarkets.com/otcapi/company/financial-report/103898/content

So basically, it sounds like the meeting never actually happened in 2013.

There was also this publication from a couple days before...

https://backend.otcmarkets.com/otcapi/company/financial-report/103732/content

Then nothing ever came of it.

So actually HAVING the meeting now in January 2018 is further along than we got in 2013.